Clinical Trials in Salt Lake City

Showing 821-840 of 7,997 trials

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

NCT07002060

The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit. * The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6. Number of Participants: A total of 640 participants are expected to be included in the study in a 3:1 ratio (vYF: YF-VAX): Group 1: vYF; N=480 Group 2: YF-VAX; N=160 Study Arms and Duration: Randomized, active control (YF-VAX). 6 months duration per participants. Eligible participants will be randomized in a 3:1 ratio to receive, subcutaneously, a single dose of vYF or YF-VAX vaccines on D01.

Yellow Fever Immunization

Sanofi640 participantsStarted May 2025

Decatur, Georgia, United States • New Orleans, Louisiana, United States • Baltimore, Maryland, United States +4 more locations

COMPLETEDPHASE2< 1 mile

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

NCT05459571

The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Relapsed or Refractory Large B-cell Lymphoma

Kite, A Gilead Company35 participantsStarted Aug 2022

Duarte, California, United States • Los Angeles, California, United States • Denver, Colorado, United States +13 more locations

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Find Trials by Condition in Salt Lake City

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

A Phase 2b Study of Zagociguat in Patients With MELAS

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Pragmatic Clinical Trial

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma